Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP as Blood Glucose Stabilizer
NCT01048268Phase 2Completed
- Sponsor
- Gentofte Hospital
- Start
- Dec 2009
- Primary completion
- Apr 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glucose-dependent insulinotropic polypeptide[1-42] in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Gentofte Hospital. Primary endpoint: Difference in glucagon secretion. Started Dec 2009; status: completed.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01048268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01048268.